CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aytu BioScience, Inc. - AYTU CFD

2.682
2.9%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.106
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.762
Open 2.732
1-Year Change 52.2%
Day's Range 2.662 - 2.792
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 16, 2024 2.762 -0.010 -0.36% 2.772 2.802 2.702
Jul 15, 2024 2.812 0.150 5.63% 2.662 2.812 2.662
Jul 12, 2024 2.682 -0.100 -3.59% 2.782 2.832 2.682
Jul 11, 2024 2.802 0.090 3.32% 2.712 2.842 2.712
Jul 10, 2024 2.772 0.010 0.36% 2.762 2.872 2.702
Jul 9, 2024 2.822 0.090 3.29% 2.732 2.882 2.702
Jul 8, 2024 2.842 0.100 3.65% 2.742 2.872 2.712
Jul 5, 2024 2.802 0.070 2.56% 2.732 2.872 2.732
Jul 3, 2024 2.762 0.040 1.47% 2.722 2.782 2.722
Jul 2, 2024 2.822 0.090 3.29% 2.732 2.832 2.662
Jul 1, 2024 2.812 0.080 2.93% 2.732 2.852 2.652
Jun 28, 2024 2.832 0.060 2.16% 2.772 2.832 2.772
Jun 27, 2024 2.822 0.050 1.80% 2.772 2.872 2.772
Jun 26, 2024 2.842 0.070 2.53% 2.772 2.872 2.752
Jun 25, 2024 2.892 0.150 5.47% 2.742 2.922 2.742
Jun 24, 2024 2.852 0.120 4.39% 2.732 2.902 2.732
Jun 21, 2024 2.742 0.000 0.00% 2.742 2.802 2.742
Jun 20, 2024 2.732 -0.070 -2.50% 2.802 2.842 2.702
Jun 18, 2024 2.732 -0.130 -4.54% 2.862 2.922 2.732
Jun 17, 2024 2.782 -0.010 -0.36% 2.792 2.852 2.682

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aytu BioScience, Inc. Company profile

About Aytu Biopharma Inc

Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Financial summary

BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.

Equity composition

Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.

Industry: Pharmaceuticals (NEC)

7900 E. Union Avenue
Suite 920
DENVER
COLORADO 80237
US

People also watch

XRP/USD

0.61 Price
+4.030% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,388.67 Price
-1.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,845.10 Price
-2.650% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,456.67 Price
-0.540% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.31

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading